About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Astellas Pharma Inc. et al. v. Apotex Inc. et al.
1:15-cv-00857; filed September 22, 2015 in the District Court of Delaware

• Plaintiffs:  Astellas Pharma Inc.; Astellas US LLC; Astellas Pharma US, Inc.
• Defendants:  Apotex Inc.; Apotex Corp.

Infringement of U.S. Patent Nos. 6,107,458 ("Cyclic Hexapeptides Having Antibiotic Activity," issued August 22, 2000) and 6,774,104 ("Stabilized Pharmaceutical Composition in Lyophilized Form," issued August 10, 2004) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Astellas' Mycamine® (micafungin sodium, used for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses; esophageal candidiasis; and prophylaxis of Candida infections in hematopoietic stem cell transplant recipients).  View the complaint here.

Taro Pharmaceuticals U.S.A., Inc. et al. v. Perrigo UK FINCO Limited Partnership
1:15-cv-00859; filed September 22, 2015 in the District Court of Delaware

• Plaintiffs:  Taro Pharmaceuticals U.S.A., Inc.; Taro Pharmaceuticals North America, Inc.
• Defendant:  Perrigo UK FINCO Limited Partnership

Infringement of U.S. Patent Nos. 8,277,780 ("Stable Liquid Desoximetasone Compositions with Reduced Oxidized Impurity" issued October 2, 2012) and 8,715,624 (same title, issued May 6, 2014) following a Paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Taro's Topicort® (desoximetasone topical spray, used for the treatment of plaque psoriasis).  View the complaint here.

AstraZeneca Pharmaceuticals LP et al. v. Mylan Pharmaceuticals Inc. et al.
1:15-cv-07009; filed September 21, 2015 in the District Court of New Jersey

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; Astrazeneca UK Limited; AstraZeneca AB
• Defendants:  Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Ltd.

Infringement of U.S. Patent Nos. 6,774,122 ("Formulation," issued August 10, 2004), 7,456,160 (same title, issued November 25, 2008), 8,329,680 (same title, issued December 11, 2012), and 8,466,139 (same title, issued June 18, 2013) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of AstraZeneca's Faslodex® (fulvestrant injection, used to treat hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy).  View the complaint here.

Bayer Pharma AG et al. v. Alembic Pharmaceuticals Limited et al.
1:15-cv-00832; filed September 18, 2015 in the District Court of Delaware

• Plaintiffs:  Bayer Pharma AG; Bayer Intellectual Property GMBH; Bayer HealthCare Pharmaceuticals Inc.
• Defendants:  Alembic Pharmaceuticals Limited; Alembic Global Holding SA; Alembic Pharmaceuticals, Inc.

Infringement of U.S. Patent No. 8,613,950 ("Pharmaceutical Forms With Improved Pharmacokinetic Properties," issued December 4, 2013) following a Paragraph IV certification as part of Alembic's filing of an ANDA to manufacture a generic version of Bayer's Staxyn® (vardenafil hydrochloride, used to treat erectile dysfunction).  View the complaint here.

Amgen Inc. et al. v. Hospira, Inc.
1:15-cv-00839; filed September 18, 2015 in the District Court of Delaware

• Plaintiffs:  Amgen Inc.; Amgen Manufacturing, Ltd.
• Defendant:  Hospira, Inc.

Infringement of U.S. Patent Nos. 5,856,298 ("Erythropoietin Isoforms," issued January 5, 1999) and 5,756,349 ("Production of Erythropoietin," issued May 26, 1998) based on Hospira's filing of a BLA to market a biosimilar version of Amgen's Epogen® (erythropoietin, used to treat anemia).  View the complaint here.

Vivus, Inc. v. Teva Pharmaceuticals USA, Inc. et al.
2:15-cv-06957; filed September 18, 2015 in the District Court of New Jersey

• Plaintiff:  Vivus, Inc.
• Defendants:  Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.

Infringement of U.S. Patent Nos. 9,011,905 ("Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof," issued April 21, 2015) and 9,011,906 ("Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity" issued April 21, 2015) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Vivus' Qsymia® (phentermine and topiramate extended-release capsules, used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management).  View the complaint here.